# Kingray Capital

> Kingray Capital is a VC fund backing Biotechnology and Electronics. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 18
- Last investment: May 2026
- Lead investor: 50%
- Last updated: Aug 2026

Kingray Capital is an Investment firm.

## Contacts

5 contacts available for Kingray Capital. Shizune tracks 1 team members at Kingray Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kingray-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 17% |
| Electronics | 2 | 11% |
| Therapeutics | 2 | 11% |
| Semiconductor | 2 | 11% |
| Pharmaceutical | 2 | 11% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 11% |
| Seed | 1 | 6% |
| Series B | 1 | 6% |
| Series C | 1 | 6% |
| Series D | 1 | 6% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Huang Pu | Managing Partner | 3 | https://shizune.co/investors/profile/huang-pu-d06f |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Immunocan | Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | $36.8M | Series A | May 13, 2026 |  |
| Tauren | Tauren is a domestic and hybrid design enterprise of analog and analog-digital chips. At present, the company has won the recognition of the top first-line customers and the strong support of the first-line investment institutions; in the future, it will continue to cultivate the analog and analog-digital hybrid design track, and provide highlycompetitive standardized products for the market landing demand. Provide customers with stable and first-class quality semiconductor products. |  | Series E | Jan 21, 2026 |  |
| Panmeng Semiconductor | Panmeng Semiconductor produces semiconductor-grade silicon wafers and provides grinding, etching, and polishing services, which are critical for advancing the domestic semiconductor and electronics industries. | $14.2M | Series A | Dec 18, 2025 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $75.1M | Series C | Jan 07, 2025 |  |
| Immunocan | Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. |  | Venture - Series Unknown | Jan 01, 2025 |  |
| IMPACT Therapeutics | IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. | $55.3M | Series D | Apr 19, 2024 |  |
| TopOlefin Technology | TopOlefin Technology engages in the research, development and production of advanced, green, intelligent and high-end polymer new materials. | $141.7M | Series B | Jul 21, 2023 |  |
| Zhitong Precision | Zhitong Precision is a producer of industrial robots. They provide products that include machine tools, wind power, AGV cars, ships, construction machinery, and high-speed rail. They offer components and industrial automation production line solutions. |  | Venture - Series Unknown | Mar 13, 2023 |  |
| Immunocan | Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. |  | Venture - Series Unknown | Jan 01, 2023 |  |
| Trinomab | Trinomab is a Healthcare company. | $104.7M | Venture - Series Unknown | Nov 29, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [Xicheng Jinrui](https://shizune.co/investors/profile/xicheng-jinrui) — VC Fund, 7 deals together
- [ShenZhen GTJA Investment Group](https://shizune.co/investors/profile/shenzhen-gtja-investment-group) — VC Fund, 3 deals together
- [Taiyu Investment](https://shizune.co/investors/profile/taiyu-investment) — VC Fund, 3 deals together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 2 deals together
- [Guojin Group](https://shizune.co/investors/profile/guojin-group) — VC Fund, 2 deals together
- [Beijing E-town International Investment & Development](https://shizune.co/investors/profile/beiid) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kingray Capital invest in?

Kingray Capital invests primarily in Biotechnology, Electronics and Therapeutics startups, most often at Series A and Seed stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kingray Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kingray Capital?

The team at Kingray Capital includes Huang Pu (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co